{"product_id":"the-maudsley-deprescribing-guidelines-antidepressants-benzodiazepines-gabapentinoids-and-z-drugs-9781119822981","title":"The Maudsley Deprescribing Guidelines: Antidepressants, Benzodiazepines, Gabapentinoids and Z-Drugs","description":"\u003cb\u003eThe Maudsley\u003csup\u003e(R)\u003c\/sup\u003e Deprescribing Guidelines\u003c\/b\u003e \u003cp\u003e \u003cb\u003eComprehensive resource describing guidelines for safely reducing or stopping (deprescribing) antidepressants, benzodiazepines, gabapentinoids and z-drugs for patients, including step-by-step guidance for all commonly used medications, covering common pitfalls, troubleshooting, supportive strategies, and more.\u003c\/b\u003e \u003c\/p\u003e\u003cp\u003eMost formal guidance on psychiatric medication relates to starting or switching medications with minimal guidance on deprescribing medication. In 2023, the World Health Organisation and the United Nations called for patients, as a human right, to be informed of their right to discontinue treatment and to receive support to do so. \u003c\/p\u003e\u003cp\u003e\u003ci\u003eThe Maudsley Deprescribing Guidelines \u003c\/i\u003efills a significant gap in guidance for clinicians by providing comprehensive and authoritative information on this important aspect of treatment. \u003c\/p\u003e\u003cp\u003eThis evidence-based handbook provides an overview of principles to be used in deprescribing. This is derived from fundamental scientific principles and the latest research on this topic, combined with emerging insights from clinical practice (including from patient experts). \u003c\/p\u003e\u003cp\u003eBuilding on the recognised brand of \u003ci\u003eThe Maudsley Prescribing Guidelines\u003c\/i\u003e, and the prominence of the authors' work, including in \u003ci\u003eThe Lancet Psychiatry \u003c\/i\u003eon tapering antidepressants (the most read article across all Lancet titles when it was released). \u003ci\u003eThe Maudsley Deprescribing Guidelines \u003c\/i\u003ecovers topics such as: \u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eWhy and when to deprescribe antidepressants, benzodiazepines, gabapentinoids and z-drugs \u003c\/li\u003e \u003cli\u003eBarriers and enablers to deprescribing including physical dependence, social circumstances, and knowledge about the discontinuation process \u003c\/li\u003e \u003cli\u003eDistinguishing withdrawal symptoms, such as poor mood, anxiety, insomnia, and a variety of physical symptoms from symptoms of the underlying disorder that medication was intended to treat \u003c\/li\u003e \u003cli\u003eThe difference between physical dependence and addiction\/substance use disorder \u003c\/li\u003e \u003cli\u003eExplanation of why and how to implement hyperbolic tapering in clinical practice \u003c\/li\u003e \u003cli\u003eSpecific guidance on formulations of medication and techniques for making gradual reductions, including using liquid forms of medication, and other approaches\u003c\/li\u003e \u003cli\u003eStep-by-step guidance for safely stopping all commonly used antidepressants, benzodiazepines, gabapentinoids and z-drugs, including fast, moderate and slow tapering regimens or schedules for each drug, and guidance on how to tailor these to an individual \u003c\/li\u003e \u003cli\u003eTroubleshooting issues which can arise on stopping these medications, including akathisia, withdrawal symptoms, acute or protracted, and relapse.\u003c\/li\u003e\n\u003c\/ul\u003e \u003cp\u003eWritten for anyone interested in safe deprescribing of psychiatric medications including psychiatrists, GPs, pharmacists, nurses, medical trainees, and interested members of the public. \u003ci\u003eThe Maudsley Deprescribing Guidelines \u003c\/i\u003eis an essential resource on the subject that provides practical guidance on how to improve patient outcomes in this field of medicine.\u003cbr\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eAbout the Author\u003c\/b\u003e\u003cbr\u003e\u003c\/p\u003e\u003cp\u003e\u003cb\u003eMark Horowitz, BA, BSc(Med), MBBS(Hons), MSc, GDipPsych, PhD, \u003c\/b\u003e is a trainee psychiatrist and Clinical Research Fellow at North East London NHS Trust, where he runs a psychiatric drug deprescribing clinic. He is an Honorary Research Fellow at University College London and he co-authored the Royal College of Psychiatrists guide on 'Stopping antidepressants'. He has authored multiple academic papers on how to safely stop psychiatric drugs in high impact journals, and lectured on this topic around the world to doctors, pharmacists and the public. He was commissioned by Health Education England to prepare a module on safe deprescribing of antidepressants for prescribers in the National Health Service (NHS). He has lived experience of stopping psychiatric drugs which informs most of his work.\u003c\/p\u003e \u003cp\u003e\u003cb\u003eDavid Taylor, PhD, FFRPS, FRPharmS, FRCPEdin, FRCPsych(Hon), \u003c\/b\u003e is Director of Pharmacy and Pathology at the South London and Maudsley NHS Trust and Professor of Psychopharmacology at King's College, London. He is the lead author of the Maudsley Prescribing Guidelines in Psychiatry and Editor-in-Chief of Therapeutic Advances in Psychopharmacology. He co-authored the Royal College of Psychiatrists guide on 'Stopping antidepressants'. His pharmacy department ran a medication help-line for a decade which fielded queries largely related to withdrawal from psychiatric drugs. He has personal experience of stopping psychiatric drugs.\u003c\/p\u003e\u003cbr\u003e","brand":"Wiley-Blackwell","offers":[{"title":"Default Title","offer_id":50613676540178,"sku":"9781119822981","price":64.99,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0831\/4771\/8930\/files\/img_2ca7db1c-659e-476b-ab3b-76992dfc69b8.jpg?v=1732413659","url":"https:\/\/surprise-castle.myshopify.com\/products\/the-maudsley-deprescribing-guidelines-antidepressants-benzodiazepines-gabapentinoids-and-z-drugs-9781119822981","provider":"Surprise Castle","version":"1.0","type":"link"}